HHS Policy Allows Compounding Pharmacies to Produce Popular Unproven Peptides

The Department of Health and Human Services (HHS) announced a new policy that will allow small compounding pharmacies to produce a half-dozen popular wellness peptides without fear of federal enforcement. This move effectively brings substances that have long existed in a legal gray market into a regulated pharmacy setting, though it does so by bypassing the standard FDA drug approval process.

The policy changes how the U.S. government handles "research-use" chemicals. For years, wellness influencers and some clinicians have promoted these peptides for everything from metabolic health to wound healing, despite a lack of rigorous safety data. By exercising enforcement discretion, the administration is essentially choosing to look the other way when specific small-scale pharmacies manufacture these strings of amino acids.

Kennedy pushes peptides into the pharmacy

The driving force behind this shift is Health Secretary Robert F. Kennedy Jr., a vocal supporter of peptide therapy who has stated he has used some of these substances himself. The administration’s logic is rooted in harm reduction: they argue that compounding pharmacies provide a safer, more accountable alternative to the “research-use-only” peptides currently sold online, which are often sourced from unverified overseas suppliers.

💉 Here’s what the recent HHS peptide announcement actually means.On October 28, HHS released an interim Enforcement Discretion Policy for 503A compounding of six peptides (BPC-157, TB-500, MOTS-c, Epitalon, Semax, and KPV). The Federal Register notice publishes October 30 (FR…

— https://x.com/mattpat1/status/2115507611550540241

The policy specifically targets 503A compounding pharmacies, which are small compounders. It does not extend to “503B” outsourcing facilities, which produce larger volumes of medicine. This distinction creates a narrow window of legality that doesn’t actually change the legal status of the peptides themselves, but rather removes the threat of prosecution for the small-scale pharmacists making them.

The six peptides now accessible

While the FDA’s own scientists recommended against lifting these restrictions during a July meeting, a panel of FDA advisers voted in favor of expanded access. The resulting policy covers six specific peptides and their touted, though often unproven, applications:

BPC-157: Used for ulcerative colitis
Epitalon: Used for insomnia
KPV: Used for wound healing
MOTS-c: Used for metabolic health
Semax: Used for migraines
TB-500: Used for wound healing

Supply chains struggle to meet demand

Even with the green light, patients shouldn’t expect these to appear on pharmacy shelves overnight. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, warns that the limited scope of the policy means demand will likely far outstrip supply. Because the policy excludes large-scale 503B facilities, Fritzler says his company can only produce these in small quantities and may only compound one of the six approved peptides.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted that the transition will take time because ingredient suppliers must first ensure their raw materials meet the policy’s requirements. Pharmacies then have to verify those ingredients before dispensing them to patients.

“It also brings patients into a system where pharmacy standards, regulatory oversight, and serious adverse event reporting apply,” Brunner said regarding the shift away from the gray market.

Public health advocates warn of FDA sabotage

Not everyone views this as a victory for patient safety. Consumer advocacy groups argue that the policy undermines the fundamental role of the FDA. Public Citizen claims that Secretary Kennedy acted unilaterally, bypassing the typical rulemaking process to allow unproven substances into the market.

Secretary of Health and Human Services Robert F. Kennedy Jr. has supported broader access to peptides. A new policy will — Photo: wusf.org

Dr. Robert Steinbrook, Health Research Group Director at Public Citizen, argues that the move threatens public health by allowing substances to be marketed without the rigorous review required for any other new drug. The Partnership for Safe Medicines has gone a step further, filing a citizen petition urging the FDA to ignore the advisory committee’s recommendation to allow these peptides.

cGMP Video Series: Does the FDA or State Agencies Regulate Compounding Pharmacies?

“Today’s decision leaves Americans in a grey area as to whether peptides are safe or not, even though the FDA’s own scientists recommended against voting in favor of these substances due to concerns with evidence,” said Shabbir Safda, executive director of the Partnership for Safe Medicines.

The tension here is a classic clash of philosophies: one side believes that since people are already buying these substances from “sketchy” overseas sources, it is better to move them into a regulated pharmacy environment. The other side believes that by removing the enforcement barrier, the government is tacitly endorsing unproven medicine and encouraging clinicians to prescribe substances that have not proven their safety in clinical trials.

As compounding pharmacies begin the slow process of verifying suppliers and prepping their facilities, the medical community remains divided on whether this is a pragmatic safety measure or a dangerous erosion of drug oversight.